Literature DB >> 21314240

Eradication therapies for HIV Infection: time to begin again.

David M Margolis1.   

Abstract

Despite the success of antiretroviral therapy (ART) in decreasing mortality for HIV-1-infected patients, ART has not cured the disease. A persistent viral reservoir in the T cells of HIV patients receiving potent ART is a significant barrier preventing eradication of HIV infection. We will briefly review what is known about the mechanisms that establish and maintain persistent HIV infection despite ART, to create a framework in which to consider approaches to the clearance or eradication of infection ("cure"), or to allow clinical stability in the absence of ART ("functional cure"). With regard to eradication therapies, it could be said that as a field our position is analogous to that of ART early in the HIV pandemic. As then we must now simultaneously develop and optimize platforms and paradigms for the discovery and testing of eradication therapies, and begin to advance candidate therapies toward human testing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314240      PMCID: PMC3065332          DOI: 10.1089/AID.2011.0017

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  75 in total

1.  Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

Authors:  Nancie M Archin; Amy Espeseth; Daniel Parker; Manzoor Cheema; Daria Hazuda; David M Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

2.  Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1.

Authors:  Brandon F Keele; Loubna Tazi; Suzanne Gartner; Yiling Liu; Trever B Burgon; Jacob D Estes; Tyler C Thacker; Keith A Crandall; Justin C McArthur; Gregory F Burton
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

3.  Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency.

Authors:  Richard Pearson; Young Kyeung Kim; Joseph Hokello; Kara Lassen; Julia Friedman; Mudit Tyagi; Jonathan Karn
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

4.  A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.

Authors:  Kara S Keedy; Nancie M Archin; Adam T Gates; Amy Espeseth; Daria J Hazuda; David M Margolis
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

5.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Authors:  Yefei Han; Yijie B Lin; Wenfeng An; Jie Xu; Hung-Chih Yang; Karen O'Connell; Dominic Dordai; Jef D Boeke; Janet D Siliciano; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

6.  Transcriptional interference antagonizes proviral gene expression to promote HIV latency.

Authors:  Tina Lenasi; Xavier Contreras; B Matija Peterlin
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

7.  Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells.

Authors:  Xavier Contreras; Marc Schweneker; Ching-Shih Chen; Joseph M McCune; Steven G Deeks; Jeffrey Martin; B Matija Peterlin
Journal:  J Biol Chem       Date:  2009-01-09       Impact factor: 5.157

8.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

9.  Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells.

Authors:  Gautam K Sahu; David Paar; Simon D W Frost; Melissa M Smith; Scott Weaver; Miles W Cloyd
Journal:  J Med Virol       Date:  2009-01       Impact factor: 2.327

10.  "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence.

Authors:  Andrea Savarino; Antonello Mai; Sandro Norelli; Sary El Daker; Sergio Valente; Dante Rotili; Lucia Altucci; Anna Teresa Palamara; Enrico Garaci
Journal:  Retrovirology       Date:  2009-06-02       Impact factor: 4.602

View more
  21 in total

1.  Simian Immunodeficiency Virus SIVsab Infection of Rhesus Macaques as a Model of Complete Immunological Suppression with Persistent Reservoirs of Replication-Competent Virus: Implications for Cure Research.

Authors:  Dongzhu Ma; Cuiling Xu; Anthony R Cillo; Benjamin Policicchio; Jan Kristoff; George Haret-Richter; John W Mellors; Ivona Pandrea; Cristian Apetrei
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

Review 2.  HIV prevention transformed: the new prevention research agenda.

Authors:  Nancy S Padian; Sandra I McCoy; Salim S Abdool Karim; Nina Hasen; Julia Kim; Michael Bartos; Elly Katabira; Stefano M Bertozzi; Bernhard Schwartländer; Myron S Cohen
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

3.  Cutting Edge: T Regulatory Cell Depletion Reactivates Latent Simian Immunodeficiency Virus (SIV) in Controller Macaques While Boosting SIV-Specific T Lymphocytes.

Authors:  Tianyu He; Egidio Brocca-Cofano; Benjamin B Policicchio; Ranjit Sivanandham; Rajeev Gautam; Kevin D Raehtz; Cuiling Xu; Ivona Pandrea; Cristian Apetrei
Journal:  J Immunol       Date:  2016-11-11       Impact factor: 5.422

Review 4.  Eliminating the HIV reservoir.

Authors:  Alain Lafeuillade
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

5.  TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.

Authors:  So-Yon Lim; Christa E Osuna; Peter T Hraber; Joe Hesselgesser; Jeffrey M Gerold; Tiffany L Barnes; Srisowmya Sanisetty; Michael S Seaman; Mark G Lewis; Romas Geleziunas; Michael D Miller; Tomas Cihlar; William A Lee; Alison L Hill; James B Whitney
Journal:  Sci Transl Med       Date:  2018-05-02       Impact factor: 17.956

6.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

7.  Conceptualizing a Human Right to Prevention in Global HIV/AIDS Policy.

Authors:  Benjamin Mason Meier; Kristen Nichole Brugh; Yasmin Halima
Journal:  Public Health Ethics       Date:  2012-12-05       Impact factor: 1.940

Review 8.  HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.

Authors:  Mattia Bonsignori; S Munir Alam; Hua-Xin Liao; Laurent Verkoczy; Georgia D Tomaras; Barton F Haynes; M Anthony Moody
Journal:  Trends Microbiol       Date:  2012-09-13       Impact factor: 17.079

9.  Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice.

Authors:  Ilona Hauber; Helga Hofmann-Sieber; Jan Chemnitz; Danilo Dubrau; Janet Chusainow; Rolf Stucka; Philip Hartjen; Axel Schambach; Patrick Ziegler; Karl Hackmann; Evelin Schröck; Udo Schumacher; Christoph Lindner; Adam Grundhoff; Christopher Baum; Markus G Manz; Frank Buchholz; Joachim Hauber
Journal:  PLoS Pathog       Date:  2013-09-26       Impact factor: 6.823

10.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.